#BEGIN_DRUGCARD DB00717

# AHFS_Codes:
68:12.00

# ATC_Codes:
G03AC01

# Absorption:
Absolute oral bioavailability approximately 64%

# Biotransformation:
Hepatic

# Brand_Mixtures:
Brevicon 0.5/35 (21 day) (Ethinyl Estradiol + Norethindrone)
Brevicon 0.5/35 (28 day) (Ethinyl Estradiol + Norethindrone)
Brevicon 0.5/35 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Brevicon 0.5/35 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Brevicon 1/35 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Brevicon 1/35 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Estalis 140/50 Mcg (Estradiol + Norethindrone Acetate)
Estalis 250/50 Mcg (Estradiol + Norethindrone Acetate)
Estalis Sequi (Estradiol + Norethindrone Acetate)
Estracomb (Estradiol + Norethindrone Acetate)
Femhrt 1/5 (Ethinyl Estradiol + Norethindrone Acetate)
Loestrin 1.5/30 21-day Pack (Ethinyl Estradiol + Norethindrone Acetate)
Loestrin 1.5/30 28-day Pack (Ethinyl Estradiol + Norethindrone Acetate)
Minestrin 1/20 21 (Ethinyl Estradiol + Norethindrone Acetate)
Minestrin 1/20 28 (Ethinyl Estradiol + Norethindrone Acetate)
Norinyl 1/50 (21 day) (Mestranol + Norethindrone)
Norinyl 1/50 (28 day) (Mestranol + Norethindrone)
Norinyl 1/50 - 21-day pack (Mestranol + Norethindrone)
Norinyl 1/50 - 28-day pack (Mestranol + Norethindrone)
Ortho 0.5/35 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Ortho 0.5/35 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Ortho 1/35 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Ortho 1/35 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Ortho 10/11 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Ortho 10/11 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Ortho 7/7/7 Tablets (21 day) (Ethinyl Estradiol + Norethindrone)
Ortho 7/7/7 Tablets (28 day) (Ethinyl Estradiol + Norethindrone)
Ortho-Novum 1/50 Tablets (21 day) (Mestranol + Norethindrone)
Ortho-Novum 1/50 Tablets (28 day) (Mestranol + Norethindrone)
Select 1/35 (21 day) (Ethinyl Estradiol + Norethindrone)
Select 1/35 (28 day) (Ethinyl Estradiol + Norethindrone)
Synphasic (21 day) (Ethinyl Estradiol + Norethindrone)
Synphasic (28 day) (Ethinyl Estradiol + Norethindrone)

# Brand_Names:
Anhydrohydroxynorprogesterone
Anovulatorio
Anovule
Aygestin
Binovum
Brevicon
Brevinor
Brevinor 21
Brevinor 28
Brevinor-1 21
Brevinor-1 28
Camila
Ciclovulan
Conceplan
Conludaf
Conludag
Demulen
ENT
Errin
Estrinor
Ethinylnortestosterone
Ethynylmortestosterone
Ethynylnortestosterone
Gencept
Genora
Gestest
Jenest
Jenest-28
Loestrin
Loestrin 24 Fe
Menzol
Microneth
Micronett
Micronor
Micronovum
Milli
Mini-Pe
Mini-Pill
Minovlar
N.E.E.
NET
Nelova
Neocon
Nodiol
Nor-Q.D.
Nor-Qd
Noraethisteronum
Noralutin
Norcept
Norcept-E
Norcolut
Noresthisterone
Norethadrone
Norethin
Norethin 1/35 E
Norethin 1/50 M
Norethindrone Acetate
Norethindrone Norethisterone
Norethisteron
Norethisterone
Norethisterone [Progestins]
Norethisteronum [INN-Latin]
Norethyndron
Norethynodron
Norethynodrone
Noretisterona [INN-Spanish]
Noretisterone [Dcit]
Norfor
Norgestin
Noriday
Noriday 28
Norimin
Norlutate
Norluten
Norlutin
Norluton
Normapause
Norpregneninlone
Norpregneninolone
Norpregneninotone
Orlest
Ortho 1 35
Ortho 7 7 7
Ortho-Novum 1 35
Ortho-Novum 1 50
Ortho-Novum 7 7 7
Ovysmen
Ovysmen 0.5 35
Ovysmen 1 35
Palonyl
Perovex
Primolut N
Primolut-N
Proluteasi
Synphase
Synphasic 28
Tri-Norinyl
Triella
Trinovum
Trinovum 21
Utovlan
Utovlar

# CAS_Registry_Number:
68-22-4

# ChEBI_ID:
7627

# Chemical_Formula:
C20H26O2

# Chemical_IUPAC_Name:
(1S,2R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
23760

# Description:
A synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Contraceptives, Oral, Synthetic
Progestins

# Drug_Interactions:
Acitretin	Acitretine may cause a loss of contraceptive effect
Amobarbital	This product may cause a slight decrease of contraceptive effect
Aprobarbital	This product may cause a slight decrease of contraceptive effect
Artemether	Artemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
Bexarotene	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
Bosentan	Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
Butabarbital	This product may cause a slight decrease of contraceptive effect
Butalbital	This product may cause a slight decrease of contraceptive effect
Butethal	This product may cause a slight decrease of contraceptive effect
Carbamazepine	This product may cause a slight decrease of contraceptive effect
Colesevelam	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
Ethotoin	This product may cause a slight decrease of contraceptive effect
Fosphenytoin	This product may cause a slight decrease of contraceptive effect
Griseofulvin	This product may cause a slight decrease of contraceptive effect
Heptabarbital	This product may cause a slight decrease of contraceptive effect
Hexobarbital	This product may cause a slight decrease of contraceptive effect
Lamotrigine	The oral contraceptive decreases the effect of lamotrigine
Mephenytoin	This product may cause a slight decrease of contraceptive effect
Methohexital	This product may cause a slight decrease of contraceptive effect
Methylphenobarbital	This product may cause a slight decrease of contraceptive effect
Pentobarbital	This product may cause a slight decrease of contraceptive effect
Phenobarbital	This product may cause a slight decrease of contraceptive effect
Phenytoin	This product may cause a slight decrease of contraceptive effect
Pioglitazone	Possible loss of contraceptive effect
Primidone	This product may cause a slight decrease of contraceptive effect
Rifabutin	Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
Rifampin	This product may cause a slight decrease of contraceptive effect
Rifapentine	This product may cause a slight decrease of contraceptive effect
Rufinamide	Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification
Secobarbital	This product may cause a slight decrease of contraceptive effect
St. John's Wort	St. John's Wort could reduce the contraceptive effect
Talbutal	This product may cause a slight decrease of contraceptive effect
Thiopental	Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
Tizanidine	The contraceptive increases the effect of tizanidine
Tretinoin	Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy.
Troglitazone	Possible loss of contraceptive effect
Warfarin	Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.97

# Experimental_Logs:
-4.57

# Experimental_Water_Solubility:
7.04 mg/L (at 25 °C)

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Norethindrone

# HET_ID:
NDR

# Half_Life:
7 hours

# InChI_Identifier:
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

# InChI_Key:
InChIKey=VIKNJXKGJWUCNN-XGXHKTLJSA-N

# Indication:
For use as an oral contraceptive in the prevention of pregnancy.

# KEGG_Compound_ID:
C05028

# KEGG_Drug_ID:
D00182

# LIMS_Drug_ID:
717

# Mechanism_Of_Action:
Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

# Melting_Point:
203.5 °C

# Molecular_Weight_Avg:
298.4192

# Molecular_Weight_Mono:
298.193280076

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ayg1666.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450651

# Pharmacology:
Norethindrone is a synthetic oral progestin. It is used for contraception or to treat such conditions as secondary amenorrhea, abnormal uterine bleeding, and endometriosis. As an oral contraceptive, norethindrone is available as either a single agent or in combination with an estrogen.

# Predicted_LogP_Hydrophobicity:
2.72

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
6.68e-03 g/l

# Primary_Accession_No:
DB00717

# Protein_Binding:
>95%

# PubChem_Compound_ID:
6230

# PubChem_Substance_ID:
46504816

# RxList_Link:
http://www.rxlist.com/cgi/generic2/norethin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00679

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:35 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Norethindrone

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_3_ID:
6016

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_4_ID:
6107

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P24462

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10494488	Mendoza-Rodriguez CA, Camacho-Arroyo I, Garcia GA, Cerbon MA: Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites. Contraception. 1999 May;59(5):339-43.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15189034	Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
15261304	Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F: Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):21-7.
16084894	Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91.
7711211	Pasapera AM, Cerbon MA, Castro I, Gutierrez R, Camacho-Arroyo I, Garcia GA, Perez-Palacios G: Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. Biol Reprod. 1995 Feb;52(2):426-32.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PGR

# Drug_Target_1_GenBank_ID_Gene:
X51730

# Drug_Target_1_GenBank_ID_Protein:
35652

# Drug_Target_1_GeneCard_ID:
PGR

# Drug_Target_1_Gene_Name:
PGR

# Drug_Target_1_Gene_Sequence:
>2802 bp
ATGACTGAGCTGAAGGCAAAGGGTCCCCGGGCTCCCCACGTGGCGGGCGGCCCGCCCTCC
CCCGAGGTCGGATCCCCACTGCTGTGTCGCCCAGCCGCAGGTCCGTTCCCGGGGAGCCAG
ACCTCGGACACCTTGCCTGAAGTTTCGGCCATACCTATCTCCCTGGACGGGCTACTCTTC
CCTCGGCCCTGCCAGGGACAGGACCCCTCCGACGAAAAGACGCAGGACCAGCAGTCGCTG
TCGGACGTGGAGGGCGCATATTCCAGAGCTGAAGCTACAAGGGGTGCTGGAGGCAGCAGT
TCTAGTCCCCCAGAAAAGGACAGCGGACTGCTGGACAGTGTCTTGGACACTCTGTTGGCG
CCCTCAGGTCCCGGGCAGAGCCAACCCAGCCCTCCCGCCTGCGAGGTCACCAGCTCTTGG
TGCCTGTTTGGCCCCGAACTTCCCGAAGATCCACCGGCTGCCCCCGCCACCCAGCGGGTG
TTGTCCCCGCTCATGAGCCGGTCCGGGTGCAAGGTTGGAGACAGCTCCGGGACGGCAGCT
GCCCATAAAGTGCTGCCCCGGGGCCTGTCACCAGCCCGGCAGCTGCTGCTCCCGGCCTCT
GAGAGCCCTCACTGGTCCGGGGCCCCAGTGAAGCCGTCTCCGCAGGCCGCTGCGGTGGAG
GTTGAGGAGGAGGATAGCTCTGAGTCCGAGGAGTCTGCGGGTCCGCTTCTGAAGGGCAAA
CCTCGGGCTCTGGGTGGCGCGGCGGCTGGAGGAGGAGCCGCGGCTTGTCCGCCGGGGGCG
GCAGCAGGAGGCGTCGCCCTGGTCCCCAAGGAAGATTCCCGCTTCTCAGCGCCCAGGGTC
GCCCTGGTGGAGCAGGACGCGCCGATGGCGCCCGGGCGCTCCCCGCTGGCCACCACGGTG
ATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCCCGCACT
CGGCAGCTGCTGGAAGACGAAAGTTACGACGGCGGGGCCGGGGCTGCCAGCGCCTTTGCC
CCGCCGCGGACTTCACCCTGTGCCTCGTCCACCCCGGTCGCTGTAGGCGACTTCCCCGAC
TGCGCGTACCCGCCCGACGCCGAGCCCAAGGACGACGCGTACCCTCTCTATAGCGACTTC
CAGCCGCCCGCTCTAAAGATAAAGGAGGAGGAGGAAGGCGCGGAGGCCTCCGCGCGCTCC
CCGCGTTCCTACCTTGTGGCCGGTGCCAACCCCGCAGCCTTCCCGGATTTCCCGTTGGGG
CCACCGCCCCCGCTGCCGCCGCGAGCGACCCCATCCAGACCCGGGGAAGCGGCGGTGACG
GCCGCACCCGCCAGTGCCTCAGTCTCGTCTGCGTCCTCCTCGGGGTCGACCCTGGAGTGC
ATCCTGTACAAAGCGGAGGGCGCGCCGCCCCAGCAGGGCCCGTTCGCGCCGCCGCCCTGC
AAGGCGCCGGGCGCGAGCGGCTGCCTGCTCCCGCGGGACGGCCTGCCCTCCACCTCCGCC
TCTGCCGCCGCCGCCGGGGCGGCCCCCGCGCTCTACCCTGCACTCGGCCTCAACGGGCTC
CCGCAGCTCGGCTACCAGGCCGCCGTGCTCAAGGAGGGCCTGCCGCAGGTCTACCCGCCC
TATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGCTTCGAG
TCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTATGGT
GTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCACAAC
TACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGCCCA
GCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGTCGAAAATTTAAA
AAGTTCAATAAAGTCAGAGTTGTGAGAGCACTGGATGCTGTTGCTCTCCCACAGCCATTG
GGCGTTCCAAATGAAAGCCAAGCCCTAAGCCAGAGATTCACTTTTTCACCAGGTCAAGAC
ATACAGTTGATTCCACCACTGATCAACCTGTTAATGAGCATTGAACCAGATGTGATCTAT
GCAGGACATGACAACACAAAACCTGACACCTCCAGTTCTTTGCTGACAAGTCTTAATCAA
CTAGGCGAGAGGCAACTTCTTTCAGTAGTCAAGTGGTCTAAATCATTGCCAGGTTTTCGA
AACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATGGTG
TTTGGTCTAGGATGGAGATCCTACAAACATGTCAGTGGGCAGATGCTGTATTTTGCACCT
GATCTAATACTAAATGAACAGCGGATGAAAGAATCATCATTCTATTCATTATGCCTTACC
ATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTCTGT
ATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGAAGTCAAACCCAG
TTTGAGGAGATGAGGTCAAGCTACATTAGAGAGCTCATCAAGGCAATTGGTTTGAGGCAA
AAAGGAGTTGTGTCGAGCTCACAGCGTTTCTATCAACTTACAAAACTTCTTGATAACTTG
CATGATCTTGTCAAACAGCTTCATCTGTACTGCTTGAATACATTTATCCAGTCCCGGGCA
CTGAGTGTTGAATTTCCAGAAATGATGTCTGAAGTTATTGCTGCACAATTACCCAAGATA
TTGGCAGGGATGGTGAAACCCCTTCTCTTTCATAAAAAGTGA

# Drug_Target_1_General_Function:
Involved in transcription factor activity

# Drug_Target_1_General_References:
11110801	Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL: Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem. 2001 Mar 16;276(11):8475-83. Epub 2000 Dec 7.
2328727	Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603-14.
3551956	Misrahi M, Atger M, d'Auriol L, Loosfelt H, Meriel C, Fridlansky F, Guiochon-Mantel A, Galibert F, Milgrom E: Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun. 1987 Mar 13;143(2):740-8.
9620806	Williams SP, Sigler PB: Atomic structure of progesterone complexed with its receptor. Nature. 1998 May 28;393(6683):392-6.

# Drug_Target_1_HGNC_ID:
HGNC:8910

# Drug_Target_1_HPRD_ID:
07077

# Drug_Target_1_ID:
614

# Drug_Target_1_Locus:
11q22-q23

# Drug_Target_1_Molecular_Weight:
98982

# Drug_Target_1_Name:
Progesterone receptor

# Drug_Target_1_Number_of_Residues:
933

# Drug_Target_1_PDB_ID:
1SQN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4
PF02161	Prog_receptor

# Drug_Target_1_Protein_Sequence:
>Progesterone receptor
MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLF
PRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLA
PSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAA
AHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGK
PRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTV
MDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPD
CAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLG
PPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPC
KAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPP
YLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHN
YLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPV
GVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQ
LGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAP
DLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQ
FEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRA
LSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues

# Drug_Target_1_SwissProt_ID:
P06401

# Drug_Target_1_SwissProt_Name:
PRGR_HUMAN

# Drug_Target_1_Synonyms:
PR

# Drug_Target_1_Theoretical_pI:
6.45

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00717
